T6315

MLN8054 is a potent and selective Aurora A kinase inhibitor with an IC50 of 4 nM.

IHCH-3064 is a tumour immunotherapeutic agent that targets both the adenosine A2A receptor and HDAC. IHCH-3064 effectively binds A2AR (Ki: 2.2 nM) and selectively inhibits HDAC1 (IC50: 80.2 nM). Prexasertib Mesylate

Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is an ATP-competitive, selective, second-generation cell cycle checkpoint kinase 1 (CHK1) inhibitor (IC50<1 nM, Ki: 0.9 nM). It inhibits CHK2 (IC50: 8 nM) and RSK1 (IC50: 9 nM), induces double-stranded DNA breaks and replication mutations, triggers apoptosis, and exhibits potent anti-tumor effects.

APJ receptor agonist 5 (compound 3) is a potent and orally active apelin receptor (APJ) agonist (EC 50: 0.4 nM) with excellent pharmacokinetic profiles in rodent heart failure (HF) models and an acceptable safety profile in preclinical toxicology studies, improving cardiac function and useful for HF disease research.

Axl-IN-10 is a potent inhibitor of AXL (IC50: 5 nM).Axl-IN-10 has good pharmacokinetic properties in animals and excellent transmembrane properties.Axl-IN-10 can be used to study proliferative, allergic, autoimmune, inflammatory, transplant rejection, cancer or other mammalian diseases.

MMP-9-IN-3 is an MMP-9 inhibitor (IC50: 5.56 nM) that forms hydrogen bonds with MMP-9. MMP-9-IN-3 inhibits AKT activity (IC50: 2.11 nM). mmp-9-IN-3 is cytotoxic and induces apoptosis. mmp-9-IN-3 can be used to study cancer.

SJ000025081 is a dihydropyridine and can be used as an antimalarial agent. In a mouse malaria model, SJ000025081 significantly inhibited parasitemia in P. yoelii infection.

Antifungal agent 16 has antimicrobial activity comparable to that of ciprofloxacin and has higher antifungal activity than fluconazole.

hCAIX-IN-10 is a selective human carbonic anhydrase IX (hCA IX) inhibitor (Ki = 7.1 nM). It disrupts tumor pH regulation to inhibit proliferation and metastasis in hypoxic cancer research.

Anticancer agent 28 showed good anti-tumour effects in vivo in H22 allograft mice. anticancer agent 28 was 50 times more potent than Oridonin against K562 cells with an IC50 value of 0.09 μM.